We are live on
!
Find out more
BC
Broadwood Capital Portfolio holdings
AUM
$1.42B
1-Year Est. Return
34.72%
This Fund
S&P 500
This Quarter
Est. Return
-10.49%
1 Year Est. Return
+34.72%
3 Year Est. Return
+45.97%
5 Year Est. Return
+44.27%
10 Year Est. Return
+866.96%
AUM
$720M
AUM Growth
-$79.5M
(-9.9%)
Cap. Flow
+$5.92M
Cap. Flow
% of AUM
0.82%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
2
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMDX
Insight Molecular Diagnostics
IMDX
|
+$5.89M |
| 2 |
Lineage Cell Therapeutics
LCTX
|
+$25.4K |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 47.47% |
| 2 | Consumer Staples | 37.71% |
| 3 | Industrials | 5.99% |
Similar funds
PTC
NI
CBA
KC
EWS
IHG
SCM
PPC
Broadwood Capital's Q3 2019 Portfolio in Review
As of Q3 2019, Broadwood Capital held 7 positions worth $720M, down 9.9% from $800M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Trading was light in Q3 2019: portfolio turnover was 0%. Broadwood Capital opened no new positions and made no exits, leaving the 7-position portfolio largely intact.
By sector, the portfolio is most concentrated in Healthcare at 47% of assets, down from 48% a quarter earlier, followed by Consumer Staples and Industrials.
- Broadwood Capital added most to Insight Molecular Diagnostics in Q3 2019, an estimated $5.89M increase.
- Broadwood Capital's ten largest holdings make up 100% of its $720M portfolio in Q3 2019.
- Broadwood Capital opened 0 new positions and closed 0 in Q3 2019.
- Broadwood Capital's portfolio value fell 9.9% quarter-over-quarter to $720M.
Based on Broadwood Capital's 13F filing for Q3 2019, filed 14 Nov 2019.